Glutamine transport and glutamate synthesis pathway

The glutamine transport and glutamate synthesis pathway is a critical metabolic axis that facilitates the cellular acquisition and utilization of glutamine, the most abundant amino acid in the blood. This pathway begins with the transport of glutamine across the plasma membrane, primarily via the SLC1A5 (ASCT2) transporter, followed by its conversion into glutamate within the mitochondria by the enzyme glutaminase (GLS) (Source: PubMed, PMC4719102). Glutamate serves as a versatile intermediate, feeding into the tricarboxylic acid (TCA) cycle via alpha-ketoglutarate to support ATP production and providing nitrogen for the synthesis of nucleotides and other amino acids (Source: NIH, National Cancer Institute). In many malignancies, this pathway is hyperactivated to sustain rapid cell growth, a condition often driven by the MYC oncogene and referred to as "glutamine addiction" (Source: Nature Reviews Cancer, 2016). Consequently, components of this pathway, such as GLS and SLC1A5, have emerged as significant therapeutic targets, with inhibitors like telaglenastat undergoing clinical evaluation (Source: ClinicalTrials.gov). However, therapeutic intervention must account for the pathway's essential roles in the central nervous system, where glutamate is the primary excitatory neurotransmitter, and in the immune system, where glutamine is vital for T-cell proliferation and function (Source: Science Signaling, 2018).

Other names

GlutaminolysisGlutamine-glutamate cycleGlutamine metabolism

Inhibition of glutaminase (GLS) to prevent glutamate production and inhibition of glutamine transporters (e.g., SLC1A5) to block cellular uptake.